Lupin shares in focus after signing license and supply agreement for Semaglutide in 23 countries

January 21, 2026
Uncategorized

The Galenicum partnership will strengthen Lupin’s Semaglutide portfolio, as it stands out as a critical therapy amidst escalating issue of diabetes globally.

Lupin shares in focus after signing license and supply agreement for Semaglutide in 23 countries

Leave a ReplyCancel Reply

Meta shares jump 10% in extended trade after Q4, guidance beat expectations

Microsoft’s core cloud sales slow despite record spending; Stock falls over 5%

Tesla reports first annual sales drop on record but Q4 turns out better-than-feared

Cochin Shipyard Q3 Results: Revenue rises 18%, margin shrinks; dividend declared

GE Vernova T&D India Q3 profit jumps over 100% to ₹291 crore on strong revenue, margins, and robust orders